Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Source: CNBC Business
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at CNBC Business